{"success":true,"data":{"pressRelease":{"id":"161267","rtpr_id":"nPnbYy14Za-20261006","ticker":"PIRM","exchange":"NSE India","all_tickers":["PIRM"],"title":"Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility","author":"PR Newswire","published_at":"2026-10-06T07:00:04.315Z","article_body":"Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility\nPR Newswire\n\nMUMBAI, India, Oct. 6, 2026\n\n * The new microbiology laboratory and sterility testing suite are designed for\nGMP drug product applications.\n * This addition is part of the broader Lexington expansion and includes a\ndedicated sterility testing isolator, three new biosafety cabinets, and\nenhanced laboratory capacity.\n * The remainder of the expansion, including commercial-scale fill/finish, is\nexpected to be online in late 2027.\nMUMBAI, India, Oct. 6, 2026 /PRNewswire/ -- Piramal Pharma Solutions (\"PPS\"),\na leading global Contract Development and Manufacturing Organization (CDMO)\nand part of Piramal Pharma Ltd. (\"PPL\") (NSE: PPLPHARMA) (BSE: 543635), has\nopened a new microbiology laboratory at its sterile injectable facility in\nLexington, Kentucky. This addition marks a significant step forward in PPS'\nongoing $85 million Lexington expansion, aimed at enhancing commercial-scale\ncapabilities and improving operational efficiency. The new laboratory was\nreleased for routine GMP use on September 11, 2026, and shortly thereafter,\nits new sterility testing suite was conditionally approved, making the lab one\nof the first major components to come online in the expansion. The full\nmanufacturing expansion is expected to be operational in late 2027.\n\nThe new lab more than triples the site's existing microbiology testing space,\nsupporting improved laboratory workflow and providing additional capacity to\naccommodate future growth. The added space features three new biosafety\ncabinets, allowing PPS to run concurrent tests and reduce sample queue times.\nAll incubators have also been consolidated within the new lab, further\nstreamlining workflow and improving monitoring and accessibility across\ntesting activities.\n\nA key element of the lab is a dedicated sterility testing suite with a Grade C\nbackground environment, representing a major upgrade from the previously\nnon-classified area. At its center is a fully integrated, Grade A sterility\ntesting isolator that doubles the site's sterility testing capacity and allows\nmultiple samples to be processed simultaneously. By supporting both open and\nclosed filtration methods, the new isolator provides greater flexibility to\nmeet a wider range of product testing requirements. The area also includes\nbuilt-in pass-throughs to move samples directly from the manufacturing floor\nto the lab, reducing contamination risk and protecting product integrity.\n\nThese enhancements are expected to reduce testing times by up to 50%,\naccelerating batch releases, minimizing bottlenecks, and smoothing transitions\nas programs move from clinical to commercial stages. The new infrastructure\nalso reinforces the site's contamination control and sterility assurance\ncapabilities, while the added capacity reduces supply risk and prepares the\nsite for commercial-scale demand.\n\n\"The new microbiology laboratory represents an important milestone in our\nLexington expansion journey,\" said Nathan Richardson, VP and Site Head,\nPiramal Pharma Solutions Lexington. \"By enhancing sterility testing and\nmicrobiological quality capabilities, we are further strengthening our ability\nto support clients with high quality, reliable, and responsive services\nthroughout the product life cycle. This investment reflects our continued\ncommitment to operational excellence, patient safety, and the future growth of\nsterile injectable manufacturing in Lexington.\"\n\nThe new microbiology lab solidifies PPS' position as a leader in sterile\ninjectables, empowering Lexington to deliver high quality, reliable, and\npatient-focused services to small molecule, bioconjugate, and peptide modality\nclients worldwide.\n\nAbout Piramal Pharma Solutions\nPiramal Pharma Solutions (PPS) is a Contract Development and Manufacturing\nOrganization (CDMO) offering end-to-end development and manufacturing\nsolutions across the drug life cycle. We serve our customers through a\nglobally integrated network of facilities in North America, Europe, and Asia.\nThis enables us to offer a comprehensive range of services including drug\ndiscovery solutions, process and pharmaceutical development services, clinical\ntrial supplies, commercial supply of APIs, and finished dosage forms. We also\noffer specialized services such as the development and manufacture of highly\npotent APIs, antibody-drug conjugations, sterile fill/finish, peptide products\nand services, and potent solid oral drug products. PPS also offers development\nand manufacturing services for biologics including vaccines and gene\ntherapies, made possible through Piramal Pharma Limited's subsidiary, Yapan\nBio Private Limited.\n\nFor more information visit: Piramal Pharma Solutions\n(https://www.piramalpharmasolutions.com/)  | LinkedIn\n(https://www.linkedin.com/company/piramal-pharma-solutions/) | Facebook\n(https://www.facebook.com/piramalpharma/)  | X\n(https://twitter.com/PiramalPharma)\n\nAbout Piramal Pharma Limited\nPiramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), offers a\nportfolio of differentiated products and services through its 17 global\ndevelopment and manufacturing facilities and a global distribution network in\nover 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated\ncontract development and manufacturing organization; Piramal Critical Care\n(PCC), a complex hospital generics business; and the Piramal Consumer\nHealthcare business, selling over-the-counter consumer and wellness products.\nIn addition, one of PPL's associate companies, Abbvie Therapeutics India\nPrivate Limited, a joint venture between Abbvie and PPL, has emerged as one of\nthe market leaders in the ophthalmology therapy area in the Indian pharma\nmarket.\n\nFor more information, visit: Piramal Pharma (https://www.piramalpharma.com/)\n | LinkedIn (https://in.linkedin.com/company/lifeatpiramalpharma)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/piramal-pharma-solutions-launches-new-microbiology-laboratory-at-its-lexington-ky-sterile-injectable-facility-302895074.html\n(https://www.prnewswire.com/news-releases/piramal-pharma-solutions-launches-new-microbiology-laboratory-at-its-lexington-ky-sterile-injectable-facility-302895074.html)\n\nSOURCE Piramal Pharma Solutions\n\n\n\nFor Investor Queries: Gagan Borana, Investor Relations & Enterprise Risk Management, gagan.borana@piramal.com; For Media Queries: Madiha Vahid, Lead - Branding & Communications, madiha.vahid@piramal.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1999824/Vice-President-and-Site-Head-Lexington.jpg?id=OA2980228\nhttps://mmx.prnewswire.com/media/MS1999825/LexingtonMicroLab.jpg?id=OA2980229\nhttps://mmx.prnewswire.com/media/MS1999828/LexingtonSterilitySuite.jpg?id=OA2980230\nhttps://mmx.prnewswire.com/media/MS1321660/Piramal-Pharma-Solutions-Logo.jpg?id=OA2980231\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbYy14Za-20261006","title":"Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility","author":"PR Newswire","ticker":"PIRM","created":"2026-10-06T07:00:04.315Z","tickers":["PIRM"],"exchange":"NSE India","article_body":"Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility\nPR Newswire\n\nMUMBAI, India, Oct. 6, 2026\n\n * The new microbiology laboratory and sterility testing suite are designed for\nGMP drug product applications.\n * This addition is part of the broader Lexington expansion and includes a\ndedicated sterility testing isolator, three new biosafety cabinets, and\nenhanced laboratory capacity.\n * The remainder of the expansion, including commercial-scale fill/finish, is\nexpected to be online in late 2027.\nMUMBAI, India, Oct. 6, 2026 /PRNewswire/ -- Piramal Pharma Solutions (\"PPS\"),\na leading global Contract Development and Manufacturing Organization (CDMO)\nand part of Piramal Pharma Ltd. (\"PPL\") (NSE: PPLPHARMA) (BSE: 543635), has\nopened a new microbiology laboratory at its sterile injectable facility in\nLexington, Kentucky. This addition marks a significant step forward in PPS'\nongoing $85 million Lexington expansion, aimed at enhancing commercial-scale\ncapabilities and improving operational efficiency. The new laboratory was\nreleased for routine GMP use on September 11, 2026, and shortly thereafter,\nits new sterility testing suite was conditionally approved, making the lab one\nof the first major components to come online in the expansion. The full\nmanufacturing expansion is expected to be operational in late 2027.\n\nThe new lab more than triples the site's existing microbiology testing space,\nsupporting improved laboratory workflow and providing additional capacity to\naccommodate future growth. The added space features three new biosafety\ncabinets, allowing PPS to run concurrent tests and reduce sample queue times.\nAll incubators have also been consolidated within the new lab, further\nstreamlining workflow and improving monitoring and accessibility across\ntesting activities.\n\nA key element of the lab is a dedicated sterility testing suite with a Grade C\nbackground environment, representing a major upgrade from the previously\nnon-classified area. At its center is a fully integrated, Grade A sterility\ntesting isolator that doubles the site's sterility testing capacity and allows\nmultiple samples to be processed simultaneously. By supporting both open and\nclosed filtration methods, the new isolator provides greater flexibility to\nmeet a wider range of product testing requirements. The area also includes\nbuilt-in pass-throughs to move samples directly from the manufacturing floor\nto the lab, reducing contamination risk and protecting product integrity.\n\nThese enhancements are expected to reduce testing times by up to 50%,\naccelerating batch releases, minimizing bottlenecks, and smoothing transitions\nas programs move from clinical to commercial stages. The new infrastructure\nalso reinforces the site's contamination control and sterility assurance\ncapabilities, while the added capacity reduces supply risk and prepares the\nsite for commercial-scale demand.\n\n\"The new microbiology laboratory represents an important milestone in our\nLexington expansion journey,\" said Nathan Richardson, VP and Site Head,\nPiramal Pharma Solutions Lexington. \"By enhancing sterility testing and\nmicrobiological quality capabilities, we are further strengthening our ability\nto support clients with high quality, reliable, and responsive services\nthroughout the product life cycle. This investment reflects our continued\ncommitment to operational excellence, patient safety, and the future growth of\nsterile injectable manufacturing in Lexington.\"\n\nThe new microbiology lab solidifies PPS' position as a leader in sterile\ninjectables, empowering Lexington to deliver high quality, reliable, and\npatient-focused services to small molecule, bioconjugate, and peptide modality\nclients worldwide.\n\nAbout Piramal Pharma Solutions\nPiramal Pharma Solutions (PPS) is a Contract Development and Manufacturing\nOrganization (CDMO) offering end-to-end development and manufacturing\nsolutions across the drug life cycle. We serve our customers through a\nglobally integrated network of facilities in North America, Europe, and Asia.\nThis enables us to offer a comprehensive range of services including drug\ndiscovery solutions, process and pharmaceutical development services, clinical\ntrial supplies, commercial supply of APIs, and finished dosage forms. We also\noffer specialized services such as the development and manufacture of highly\npotent APIs, antibody-drug conjugations, sterile fill/finish, peptide products\nand services, and potent solid oral drug products. PPS also offers development\nand manufacturing services for biologics including vaccines and gene\ntherapies, made possible through Piramal Pharma Limited's subsidiary, Yapan\nBio Private Limited.\n\nFor more information visit: Piramal Pharma Solutions\n(https://www.piramalpharmasolutions.com/)  | LinkedIn\n(https://www.linkedin.com/company/piramal-pharma-solutions/) | Facebook\n(https://www.facebook.com/piramalpharma/)  | X\n(https://twitter.com/PiramalPharma)\n\nAbout Piramal Pharma Limited\nPiramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), offers a\nportfolio of differentiated products and services through its 17 global\ndevelopment and manufacturing facilities and a global distribution network in\nover 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated\ncontract development and manufacturing organization; Piramal Critical Care\n(PCC), a complex hospital generics business; and the Piramal Consumer\nHealthcare business, selling over-the-counter consumer and wellness products.\nIn addition, one of PPL's associate companies, Abbvie Therapeutics India\nPrivate Limited, a joint venture between Abbvie and PPL, has emerged as one of\nthe market leaders in the ophthalmology therapy area in the Indian pharma\nmarket.\n\nFor more information, visit: Piramal Pharma (https://www.piramalpharma.com/)\n | LinkedIn (https://in.linkedin.com/company/lifeatpiramalpharma)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/piramal-pharma-solutions-launches-new-microbiology-laboratory-at-its-lexington-ky-sterile-injectable-facility-302895074.html\n(https://www.prnewswire.com/news-releases/piramal-pharma-solutions-launches-new-microbiology-laboratory-at-its-lexington-ky-sterile-injectable-facility-302895074.html)\n\nSOURCE Piramal Pharma Solutions\n\n\n\nFor Investor Queries: Gagan Borana, Investor Relations & Enterprise Risk Management, gagan.borana@piramal.com; For Media Queries: Madiha Vahid, Lead - Branding & Communications, madiha.vahid@piramal.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1999824/Vice-President-and-Site-Head-Lexington.jpg?id=OA2980228\nhttps://mmx.prnewswire.com/media/MS1999825/LexingtonMicroLab.jpg?id=OA2980229\nhttps://mmx.prnewswire.com/media/MS1999828/LexingtonSterilitySuite.jpg?id=OA2980230\nhttps://mmx.prnewswire.com/media/MS1321660/Piramal-Pharma-Solutions-Logo.jpg?id=OA2980231\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-06T07:00:04.367319434Z","server_sent_at_ms":1791270004367},"received_at":"2026-10-06T07:00:04.417Z","source_url":"https://www.prnewswire.com/news-releases/piramal-pharma-solutions-launches-new-microbiology-laboratory-at-its-lexington-ky-sterile-injectable-facility-302895074.html"},"analysis":{"id":"149807","press_release_id":"161267","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Piramal Pharma Solutions opened a new microbiology laboratory at its sterile injectable facility in Lexington, KY, part of an $85 million site expansion.\n\nThe lab more than triples microbiology testing space, doubles sterility testing capacity via a Grade A isolator, and is expected to cut testing times by up to 50%, accelerating batch releases.\n\nThe remainder of the expansion, including commercial-scale fill/finish, is expected to be operational in late 2027.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Lexington expansion hitting milestones ahead of late-2027 commercial fill/finish ramp."},"keyFigures":{"customDimensions":{"expansion_value":"$85 million","micro_lab_space":"more than triples existing microbiology testing space","sterility_capacity":"doubles sterility testing capacity","full_expansion_online":"late 2027","testing_time_reduction":"up to 50%"}},"quotedText":"The new microbiology laboratory represents an important milestone in our Lexington expansion journey","namedEntities":{"people":[{"name":"Nathan Richardson","role":"VP and Site Head, Piramal Pharma Solutions Lexington"},{"name":"Gagan Borana","role":"Investor Relations contact"},{"name":"Madiha Vahid","role":"Lead - Branding & Communications"}],"products":["microbiology laboratory","sterility testing suite","Grade A sterility testing isolator"],"companies":[{"name":"Piramal Pharma Solutions","ticker":"PIRM","relationship":"filer"},{"name":"Piramal Pharma Ltd.","ticker":"PPLPHARMA","relationship":"parent"}],"dollarAmounts":[{"amount":"$85 million","context":"ongoing Lexington facility expansion"}]},"materialImpact":{"score":2,"reasoning":"A new GMP microbiology lab at the Lexington facility is a modest operational milestone within an ongoing $85M expansion; the commercial-scale fill/finish portion isn't online until late 2027, so no near-term revenue impact."},"tickerRelevance":{"others":[{"ticker":"PPLPHARMA","relevance":"parent company (NSE-listed)"}],"primary":"PIRM"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"foreign-listed pharma parent (NSE), OTC ADR audience","eventGravity":"facility/operational milestone, no revenue impact yet","eventGravityNote":"expansion not fully online until late 2027"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Piramal Pharma Solutions opened a new microbiology laboratory at its sterile injectable facility in Lexington, KY, part of an $85 million site expansion.\n\nThe lab more than triples microbiology testing space, doubles sterility testing capacity via a Grade A isolator, and is expected to cut testing times by up to 50%, accelerating batch releases.\n\nThe remainder of the expansion, including commercial-scale fill/finish, is expected to be operational in late 2027.","key_figures":{"customDimensions":{"expansion_value":"$85 million","micro_lab_space":"more than triples existing microbiology testing space","sterility_capacity":"doubles sterility testing capacity","full_expansion_online":"late 2027","testing_time_reduction":"up to 50%"}},"named_entities":{"people":[{"name":"Nathan Richardson","role":"VP and Site Head, Piramal Pharma Solutions Lexington"},{"name":"Gagan Borana","role":"Investor Relations contact"},{"name":"Madiha Vahid","role":"Lead - Branding & Communications"}],"products":["microbiology laboratory","sterility testing suite","Grade A sterility testing isolator"],"companies":[{"name":"Piramal Pharma Solutions","ticker":"PIRM","relationship":"filer"},{"name":"Piramal Pharma Ltd.","ticker":"PPLPHARMA","relationship":"parent"}],"dollarAmounts":[{"amount":"$85 million","context":"ongoing Lexington facility expansion"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T07:00:09.733Z","global_importance":18,"audience_relevance":12,"importance_components":{"tickerTier":"foreign-listed pharma parent (NSE), OTC ADR audience","eventGravity":"facility/operational milestone, no revenue impact yet","eventGravityNote":"expansion not fully online until late 2027"}},"durationMs":5282,"modelName":"glm-5.3-flashx"}}